Quest Diagnostics Incorporated DGX

Who We Play For, a nonprofit that championed Florida's Second Chance Act, Myelai, and Unless Health today announce the launch of a cardiac screening program at Quest Diagnostics' Sheldon Road location in Tampa, giving families a fast way to complete the electrocardiogram (ECG) heart screening now required for Florida high school athletes.

Quest Diagnostics (DGX) drew fresh attention after announcing an Apple Health integration that allows iPhone and iPad users to order a preventive lab panel with more than 50 biomarkers for US$119. The Apple Health tie-in lands after a strong run in Quest Diagnostics’ shares, with the price up 15.6% over 90 days and 35.1% year to date, even though the last month’s share price return slipped 3.9% as traders reassessed shorter term risk and reward. Scan beyond Quest Diagnostics and see how other...

Quest Diagnostics has delivered a strong run in recent years, which raises a straightforward question for investors who care about fundamentals. Is the current share price still aligned with the cash the business is expected to generate over time, or has sentiment moved ahead of its underlying economics? Over the past 3 years, Quest Diagnostics has returned 108.9%, which puts real weight on whether that gain is grounded in durable cash flows rather than just multiple expansion. A recent...

The Dow Jones index fell on the stock market today after President Trump threatened Iran. Other major indexes rose. Apple was among stocks trading near buy points.

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

The global NICU genetic testing market is forecast to grow from USD 1.74 billion in 2026 to USD 4.80 billion by 2036, at a 10.67% CAGR. Growth is driven by rising neonatal genetic disorders, rapid whole genome and exome sequencing, next-generation sequencing, chromosomal microarrays and personalized neonatal care. North America leads the market, while Asia-Pacific is expected to grow fastest. The report analyzes key trends, technologies, segments, regional opportunities and leading companies, in

Quest Diagnostics (DGX) and Labcorp (LH) shares fell in Tuesday premarket trading after the Centers

Quest Diagnostics has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Investing.com - U.S. stock index futures steadied on Tuesday, following a strong session on Wall Street that saw the benchmark S&P 500 post its best day since August, helped by gains in artificial intelligence-linked stocks.

Nearly one in three patients found to have antibodies against the bacterium that causes Lyme disease also had antibodies against one or more additional tick-borne pathogens, according to a new study by researchers from Quest Diagnostics (NYSE: DGX) and the University of North Carolina at Chapel Hill.